Moreover, we found that miR-31 also engages in an antagonistic regulatory circuit with EZH2, and loss of miR-31 expression may contribute to EZH2 overexpression in melanoma and provides a potential therapeutic axis which can be targeted by small molecule inhibitor. Here, EZH2 is linked to melanoma.